CKD-389

CKD-389 is an oral fixed-dose combination candidate developed by Chong Kun Dang for **type 2 diabetes mellitus**. Available clinical-trial evidence indicates that it combines the DPP-4 inhibitor **sitagliptin** with the SGLT2 inhibitor **dapagliflozin**; it was evaluated in healthy volunteers against the individual reference components D759 and D308 in a randomized, open-label, single-dose crossover pharmacokinetic study. Sitagliptin enhances endogenous incretin activity by inhibiting dipeptidyl peptidase-4, while dapagliflozin reduces renal glucose reabsorption through inhibition of sodium-glucose cotransporter 2.

Other names

sitagliptin + dapagliflozin